THE DEAL, AT A GLANCE
From the announcementTavo Biotherapeutics
01What it doesTavo Biotherapeutics is a Digital Health company focused on Advance Glaucoma and Retinal Disease Pipeline.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedTavo Biotherapeutics raised $17M Series A, announced 2026-06-02From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersTavo Biotherapeutics' $17M Series A is a below-median Healthcare & Life Sciences financing in an active funding tape, positioning the round as a focused early-stage…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Tavo Biotherapeutics · Financing Record
Explore source-linked visual explanations for Tavo Biotherapeutics. Unsupported claims are withheld while source review continues.
Record 5129 · Recorded date: 2026-06-02
Explore company records →